Actuate Therapeutics (ACTU): Director received 96K units

96K

Derivative units

Traded

Oct 28, 2026

Filed

Nov 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 26, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
2. Oct 28, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On October 28, 2026, Actuate Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to…”
3. Oct 28, 2026Insider · First insider buy since Jun 2025CEO purchased ~$50K of ACTU shares in the open market

What came next

1. Oct 30, 20265% stakeHexstone Capital LLC reported a passive stake (13G) of 7.7%

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Actuate Therapeutics

For Actuate Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ACTU page.

Other recent filings by Todd S Thomson, Director

• SEC Form 4 at Actuate Therapeutics (ACTU)Jan 7, 2026

The full history of Todd S Thomson, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Actuate Therapeutics

• SEC Schedule 13GOct 30, 2026
• SEC Form 4Oct 29, 2026
• SEC Form 4Jan 7, 2026
• SEC Form 4Jun 30, 2025
• SEC Form 4Jun 30, 2025
• SEC Form 4Jun 30, 2025

Everything OQRO holds on this company is on its ACTU page.